Intercept Pharmaceuticals | search
Click here to view Intercept Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- Intercept Pharmaceuticals | LinkedIn28. Intercept Pharmaceuticals | 62,002 followers on LinkedIn. Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. | We are a biopharmaceutical company ...
- Intercept Receives Complete Response Letter from FDA for - GlobeNewswireIntercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH June 22, 2023 17:45 ET | Source: Intercept Pharmaceuticals, Inc.
- FDA Accepts Intercept’s New Drug Application for OCA for the Treatment ...Updated Thu, Jan 19, 2023 4 min read. Intercept Pharmaceuticals, Inc. NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 ...
- Intercept Announces FDA Acceptance of Supplemental New Drug Application ...Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC. Intercept Pharmaceuticals, Inc. Thu, Feb 29, 2024, 8:30 AM 8 min ...
- Homepage - Intercept PharmaceuticalsInnovating to solve some of today’s toughest medical challenges. Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
More
